Respiratory Distress Syndrome (RDS)
RDS, respiratory distress syndrome formerly known as hyaline membrane disease, is a syndrome of respiratory difficulty in newborn infants caused by a deficiency of a compound called surfactant. RDS usually occurs in newborns born before 37 weeks of gestation.
RDS in a premature infant is defined as respiratory distress requiring more than 30% oxygen delivered by positive pressure using either Nasal CPAP or an ET Tube with a chest radiograph that has diffuse infiltrates with a ground glass granular appearance with air bronchograms.
Surfactant replacement therapy
Important: For having best result from Beraksurf®, early rescue therapy should be practiced.
Beraksurf® is a choice medicine for treatment of newborn infants with Respiratory Distress Syndrome (IRDS). First dose needs to be given as soon as diagnosis of RDS is made.
Ideally the dose should be given within 1 hr. of birth but definitely before 2 hours of age. A repeat dose should be given within 4 - 12 hours if the patient is still intubated and requiring more than 30 to 40% oxygen. Depend on diagnose of physician, up to four doses could be administered by around 6 h intervals.
Prophylactic therapy (before chest radiograph) can be considered in patients with respiratory distress who are intubated and are < 26 weeks gestation.
We strongly recommend using Beraksurf® for therapy and prophylaxis of RDS, since it has a very rapid adsorption and also tend to a very low surface tension near zero, inside alveoli.
Since Beraksurf® is a generic medicine, it is as effective and safe as originator brand and you
can save a lot for your family, hospital or country.